Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imexpharm's quarterly accounts payable & accrued expense
increased
from Mar. 2025 (₫166,240 Mil) to Sep. 2025 (₫220,022 Mil) but then
declined
from Sep. 2025 (₫220,022 Mil) to Mar. 2026 (₫165,477 Mil).
Imexpharm's annual accounts payable & accrued expense
increased
from Dec. 2023 (₫136,902 Mil) to Dec. 2024 (₫139,567 Mil) and
increased
from Dec. 2024 (₫139,567 Mil) to Dec. 2025 (₫149,221 Mil).
Imexpharm Accounts Payable & Accrued Expense Historical Data
* Premium members only.
The historical data trend for Imexpharm's Accounts Payable & Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.
Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.
It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.
What does a Accounts Payable & Accrued Expense of ₫165,477 Mil mean?
Imexpharm (STC:IMP) has a Accounts Payable & Accrued Expense of ₫165,477 Mil as of Mar. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Imexpharm and its competitors.
Is Imexpharm's Accounts Payable & Accrued Expense too high?
Imexpharm's current Accounts Payable & Accrued Expense is ₫165,477 Mil. Overall, Imexpharm has a GF Score™ of 99/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's Accounts Payable & Accrued Expense compare to ZTS?
Imexpharm's Accounts Payable & Accrued Expense of ₫165,477 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Drug Manufacturers company?
A good Accounts Payable & Accrued Expense depends on the Drug Manufacturers industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Imexpharm and its competitors. Imexpharm's current Accounts Payable & Accrued Expense is ₫165,477 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Significantly Undervalued. The stock's GF Value™ is ₫55,707.21, compared to a current price of ₫38,050.00 — trading 31.7% below its estimated fair value. The current Accounts Payable & Accrued Expense is ₫165,477 Mil. Imexpharm's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current Accounts Payable & Accrued Expense is ₫165,477 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imexpharm (STC:IMP) Overvalued in 2026?
Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued.
The current stock price of ₫38,050.00 is trading 31.7% below its estimated GF Value™ of ₫55,707.21.
GuruFocus considers Imexpharm to be Significantly Undervalued.
Key valuation signals for STC:IMP:
Accounts Payable & Accrued Expense: ₫165,477 Mil
GF Value™: ₫55,707.21 vs. price of ₫38,050.00 (31.7% below fair value)
No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
99GF Score
Get the complete analysis for STC:IMP
Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:IMP has been successfully added to your 
